CRISPR Medicine

Amber Bio

Company Type: Therapeutics

Main focus: Development of therapeutics based on a new gene-editing modality

Company stage: Pre-clinical

Diseases: Undisclosed

Genome-editing tool: CRISPR-based RNA-writing technology

Funding stage: Seed

Location: Cambridge, Massachusetts, United States

Website: https://www.amber.bio/

Pipeline:

Partners:


Amber Bio is a pre-clinical stage company that is investigating new ways to address genetic conditions by leveraging its novel “multi-kilobase-scale” RNA-writing technology. The technology exploits some of the newest findings within CRISPR biology to reach previously undruggable patient populations, by editing thousands of diverse mutations across patients with a single product.

See the full view ...